To reduce the number of apheresis procedures and maintain the usual rate of hematopoietic recovery in patients treated with high-dose chemotherapy, we studied the effect of adding a small volume of ex vivo expanded bone marrow to low doses of CD34 + blood stem cells. Thirty-four patients with breast cancer received G-CSF (10 g/kg/day) priming followed by a limited volume (50-100 ml) bone marrow aspiration and standard 10-liter aphereses. Marrow was expanded ex vivo using the AastromReplicell system and infused along with low doses of blood-derived CD34 + cells, collected in one apheresis. Thirty-one evaluable patients received a median CD34 + blood stem cell dose of 0.7 × 10 6 /kg (range, 0.2-2.5) and 4.7 × 10 7 nucleated cells/kg (range, 1.98-8.7) of ex vivo expanded marrow. All patients recovered with normal blood counts and engrafted 500 neutrophils/l and 20 000 platelets/l in a median of 10 and 13 days, respectively. Multivariate analysis revealed that, in addition to CD34 + lineage negative cell quantity, the quantity of stromal progenitors contained in the ex vivo expanded product correlated with engraftment outcome (r = 0.551, P = 0.004 
Infusion of an adequate quantity of CD34
+ cells is required to ensure prompt and durable hematopoietic recovery after high-dose chemotherapy. [1] [2] [3] [4] [5] [6] [7] Optimal CD34 + blood stem cell dosing appears to be dependent on a number of factors including patient diagnosis, prior therapy, stem cell source and the relative percentage of CD34 cell product. 7 Several studies have suggested that a CD34
+ blood stem cell dose of 5.0 × 10 6 cells/kg is optimal and routinely results in neutophil recovery of 500 cells/l in 8-10 days and platelet recovery of 20 000 cells/l in 11-13 days. 5, 6, 8 Conversely, patients who receive a low CD34
+ blood stem cell dose of р2.5 × 10 6 /kg, especially those receiving р1.0 × 10 6 /kg, frequently experience prolonged delays in count recovery, require substantially more blood product support, and are more likely to experience incomplete engraftment, particularly of platelets. They also are more susceptible to post-transplant myelosuppression due to radiation therapy and viral infections. [7] [8] [9] [10] [11] Attempts to increase the number of CD34 + cells collected from patients, especially poor mobilizers, include increasing the number of apheresis procedures and conducting a second round of apheresis at substantially higher doses of cytokine for mobilization. Unfortunately, these strategies have not been uniformly successful. 11, 12 In addition, exposure of patients to multiple apheresis collections has been associated with an increase in cost, infection, hypocalcemia, thrombocytopenia and contamination of the stem cell product with malignant cells. 9 In several settings, malignant cells contaminating stem cell products have been conclusively shown to contribute to disease relapse. [13] [14] [15] Thus, increasing the number of apheresis procedures to collect more CD34
+ cells does not appear to be an optimal solution for autologous transplant recipients.
Ex vivo expansion of a small volume (80-100 ml) of bone marrow using the AastromReplicell system, which has been demonstrated to be capable of restoring hematopoiesis in breast cancer patients treated with high-dose chemotherapy, may be a useful alternative for patients who require multiple apheresis procedures. 16 This approach may provide another benefit because bone marrow taken from patients with lymphoma and breast cancer and expanded in the AastromReplicell system, has been shown to be effectively purged of contaminating malignant cells. 17, 18 Use of this current approach alone, however, may not be ideal because it has been associated with delays in recovery of neutrophils and platelets when compared to blood stem cell recipients. 16 The potential for bone marrow cells expanded ex vivo to Bone Marrow Transplantation facilitate engraftment of a low dose of blood-derived CD34 + cells, however, does exist. In addition to providing an increased number of hematopoietic progenitors, expanded bone marrow contains stromal cells that appear to be capable of promoting engraftment of low doses of CD34 + cells. 19 Stromal progenitor cells have been shown to be expanded greater than 40-fold in the AastromReplicell system. 16 Therefore, in an attempt to reduce the number of apheresis procedures and improve the rate of hematopoietic recovery in breast cancer patients who were not rapid mobilizers and scheduled to receive high-dose chemotherapy, we evaluated the safety and effectiveness of adding a small volume of bone marrow expanded ex vivo using the AastromReplicell system to low doses of CD34
+ blood stem cells collected in a single apheresis procedure.
Patients and methods

Patients
Patients with high risk (stage II and III with у10 involved axillary lymph nodes) and metastatic breast cancer who met standard eligibility criteria to receive high-dose chemotherapy and blood stem cell support were eligible for study. Patients were required to have an Eastern Cooperative Oncology Group performance status of 0 to 2 and adequate pulmonary, cardiac, hepatic and renal function. All patients were human immunodeficiency virus seronegative and provided written informed consent approved by their centers' Institutional Review Board. Patients were eligible for enrollment in the study if a pre-leukapheresis bone marrow biopsy revealed a minimum cellularity of у30% and was histologically negative for tumor cell involvement.
Blood stem cell and marrow collection
Patients received G-CSF (10 g/kg/day) priming for 2 days followed by a limited volume (50 to 100 ml) bone marrow aspiration under conscious sedation on day 3. The cell concentration of the aspirated bone marrow had to meet a minimum criterion of у35 × 10 6 nucleated cells/ml in order for a patient to remain in the study. The bone marrow aspirate was cryopreserved as described previously. 20 Patients received a third dose of G-CSF after completion of the limited marrow harvest. A fourth dose of G-CSF was administered on the morning after the aspiration procedure (day 4), followed by a standard single 10-liter apheresis procedure. CD34
+ cell content in the apheresis product was determined using flow cytometry as described elsewhere. 21 Four escalating dose cohorts of CD34 + blood stem cell dose were designed into the study. To meet the objectives of the study's cohort approach, a specific CD34 + cell dose from the single apheresis product was cryopreserved. Accordingly, blood stem cells from the first cohort of patients were cryopreserved in the CD34 + cell dose range of 0.1 to Ͻ0.5 × 10 6 /kg. Patients in the second cohort had blood stem cells cryopreserved after aliquoting 0.5 × 10 6 /kg from the total apheresis product, or using the full first apheresis product if this was the CD34 + cell dose collected. Blood stem cells from the third cohort of patients were cryopreserved in the CD34 + cell dose range of Ͼ0.5 to 1.0 × 10 6 /kg following a similar process, and then the fourth cohort was cryopreserved in the Ͼ1.0 to 2.5 × 10 6 /kg range. Patients who were rapid mobilizers, as defined by a first day of apheresis yielded Ͼ2.5 × 10 6 /kg, were removed from study. As a precaution, all patients who failed to have a CD34 + cell dose of at least 1.0 × 10 6 /kg had a back-up apheresis product collected. Any patient who failed to have at least a 1.0 × 10 6 /kg cell dose following five cycles of apheresis was to be removed from study.
Marrow expansion
Twelve days prior to transplant, the cryopreserved bone marrow cells were thawed and inoculated into three, singleuse, AastromReplicell system cell culture cassettes. In each cassette, bone marrow cells were inoculated into a 750 cm 2 culture chamber containing media and were cultured for 12 days as described previously. 16 Two days prior to the completion of the ex vivo cell production, the cell culture effluent medium was sampled to allow for bacterial and fungal testing. At the completion of the cell production process on day 12 (corresponding to day 0 of the transplant), non-adherent cells were collected along with the adherent cell fraction, using 0.04% trypsin. The harvested cells were prepared for patient infusion as described previously. Within 6 h following the cell harvest from the AastromReplicell system, patients received an autologous transplant in two stages: (1) reinfusion of AastromReplicell systemproduced bone marrow-derived cells: and (2) infusion of blood stem cells of a specific CD34 + cell dose 4 h later. G-CSF (10 g/kg subcutaneous) was administered daily, beginning 4 h after completion of the cell infusions. It was continued until an absolute neutrophil count of 1500 cells/l was achieved for 3 consecutive days or a single day neutrophil count of 5000 cells/l was observed. Routine supportive care measures were followed according to institutional guidelines. Antipyretics, however, were not administered unless the patient experienced a body temperature у38.5°C. Complete blood counts were obtained daily until G-CSF was discontinued and a non-transfusiondependent platelet count of 20 000 cells/l was achieved. Platelet transfusions were administered when the count fell below 10 000 cells/l. Back-up blood stem cells were to be infused if by day 21 post stem cell infusion, a neutrophil count of 500 cells/l was not achieved. Back-up stem cells were also to be infused regardless of neutrophil recovery, if by day 28 post-infusion, the platelet count remained Ͻ20 000 cells/l. Hospital discharge occurred when a neutrophil count of у200 cells/l was achieved and a 48-h afebrile period was observed. Study follow-up continued weekly until day 100 post-transplant and then according to institutional guidelines.
In vitro assays of unexpanded and expanded cells
Total nucleated cell counts, CFU-GM and CFU-F (fibroblast) progenitor assays and flow cytometry analysis for myeloid, erythroid, multi-lineage and viability were performed before and after cell expansion. Autofluorescence of stromal cells prevented post-expansion assessment of total CD34 + cell content. Fold expansion was calculated according to the following formula: cells recovered postexpansion/cells inoculated before expansion. Cells were analyzed by a Coulter Epics XL flow cytometer (Coulter, Hialeah, FL, USA) as described previously. 16 CD34 + cells that were CD3, CD11b, CD14, CD15, CD20 and glycophorin A-negative were defined as lineage negative. In addition, routine microbiological assays were performed on the cell preparation before and after cell expansion, and on day 10 of incubation, from the effluent medium line of each cell culture cassette. The AastromReplicell system-produced cells were released for transplantation if the viability of the cell product was Ͼ80%, and preliminary results of the day 10 microbiological assays were negative.
Tumor contamination assays
Cell samples from the bone marrow inoculum, expanded bone marrow and apheresis product were evaluated for breast carcinoma tumor cell content and clonogenicity. Cell samples were shipped from the clinical sites to IMPATH/BIS, Inc. (Reseda, CA, USA) overnight at room temperature for tumor detection analysis. Samples were processed using a Ficoll density and evaluated for tumor cell content using immunocytochemistry and a clonogenic assay as described elsewhere.
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Statistical analysis
Ex vivo expansion potential: Differences in ex vivo expansion potential of bone marrow obtained from patients with a first day apheresis collection of Ͻ1 × 10 6 CD34 + cells/kg compared to patients with a first day apheresis collection of у1 × 10 6 CD34 + cells/kg was determined by independent samples assuming equal variances Student's t-test. Linear (Pearson) correlation was investigated between first day apheresis collection doses, percentage of CD34 + cells in the inoculum, and the fold-expansion of nucleated cells, CFU-GM and CFU-F.
Single and multivariate analysis:
To identify correlation between individual variables and engraftment times, Spearman rank correlation coefficients and associated two-tailed P values were computed using the Statistical Package for the Social Sciences (SPSS, Inc, Chicago, IL, USA). The Spearman correlation, a non-parametric procedure, was used because the engraftment variables in this study were not normally distributed. Upon examination of scatter plots and the Spearman results, curve estimations were completed for individual variables. Additionally, variables were examined to identify pairs of variables that could be combined in a ratio to produce a stronger Spearman correlation.
Comparison of CD34
+ blood stem cell dose cohorts: Mann-Whitney non-parametric version of t-test
Bone Marrow Transplantation was done between pairs of groups. Asymptotic P values are reported.
Results
Patient characteristics
Between March 1998 and November 1998, 35 women with breast cancer eligible for the study were enrolled concurrently at the third participating institutions. Four patients were later removed from the study; one experienced disease progression in the liver pre-transplant, and three had a first day apheresis collections of Ͼ2.5 × 10 6 /kg CD34 + cells. Thirty-one patients were thus evaluable for safety and efficacy.
The clinical characteristics of the 35 patients are listed in Table 1 . The majority of patients had high-risk locally advanced disease (74%). Prior to blood stem cell and marrow collections all patients had received chemotherapy and eight patients received radiation therapy. Regardless of stage of disease or prior treatment, all patients had adequate marrow cellularity (у30%).
Marrow and blood stem cell collection
Bone marrow was collected following G-CSF priming from 35 patients with a median nucleated cell concentration of 59.3 × 10 6 /ml (range, 36.5-99.0) in a median aspirated volume of 100 ml (range, 46-112). CD34
+ cell dose quantities collected on the first day of apheresis from the 31 patients evaluable for study ranged from 0.2 to 2.5 × 10 6 /kg (Table 2 ). All 31 patients included in the study mobilized у1.0 × 10 6 /kg CD34 + cells in a median of two apheresis procedures (range, 1-4) ( Table 3 ). Due to the dose cohort nature of the study, seven patients received only a portion of their blood-derived CD34 + cells with the remainder held as back-up (Table 4 ). All other patients received their entire first day apheresis product depending on the dose of cells collected. Table 1 Characteristics of advanced breast cancer patients at study enrollment (n = 35)
Patients
Number % Table 4 . This corresponded to a median CD34 + lineage-negative marrow cell dose of 0.12 × /kg, seven patients received only a portion of their first day apheresis product with the remainder held as back-up. In these seven patients, the CD34 + cell dose content of the first apheresis product ranged from 0.7 to 1.7 × 10 6 /kg. The other 24 patients were infused with their entire first day apheresis product (Table 4) .
Clinical outcomes
Adverse events during infusion of ex vivo expanded cells were observed in two patients. One patient, with a history of asthma, experienced transient respiratory distress requiring emergency intubation. The patient tolerated the infusion of the remaining expanded cell product and was extubated within 1 h without further difficulty. A second patient experienced a sudden onset of tonic clonic seizures and a transient episode of diffuse macular rash and hives. After appropriate treatment and stabilization, the patient recovered uneventfully and received the remaining expanded cell product. All 31 study patients engrafted (Table 3) . Neutrophil recovery to 500 cells/l and platelets to 20 000 cells/l (transfusion-independent) occurred at a median of 10 and 13 days, respectively. A median of two single donor platelet transfusions was required (range, 1-18) during the engraftment period. Patients were discharged from the transplant center a median of 11 days after stem cell infusions. 29% (9/31) of patients did not experience febrile neutropenia. None of the patients received infusion of stored back-up blood stem cells. All patients achieved platelet counts of more than 100 000 cells/l and none to date have experienced late graft failure (data not shown) at a minimum follow-up of 13 months (range, 13-21 months). These data include patient 2 (Table 4) , who because of delayed platelet recovery should have received her backup blood stem cells, but refused.
Analysis of the CD34 + blood stem cell dosing cohorts was performed by comparing the four groups (Table 5) . Patients receiving Ͻ0.5 × 10 6 CD34 + cells/kg experienced a greater median number of days to neutrophil (12 days) and platelet engraftment (21.5 days), as well as days of febrile neutropenia (4.5 days) and days to hospital discharge (13 days) when compared with patients in the other groups (P р 0.05). In contrast, patients receiving 0.5 × 10 cells/kg or greater, did not experience a significant difference in any of the measured clinical outcomes.
Tumor contamination of ex vivo expanded products
Twenty-five of the 31 study patients had bone marrow assessed by immunocytochemistry for contaminating
Bone Marrow Transplantation malignant cells. Five patients (20%) had detectable contaminating breast cancer cells in their pre-expansion small marrow harvest ranging in frequency between 1 in 10 000 nucleated marrow cells to 1 in 3 000 000. Following ex vivo expansion, expanded bone marrow from three of these patients had no detectable contamination. The other two patients had persistent detectable tumor cells, however in one of the two, the frequency diminished from 1 in 400 000 to 1 in 1 000 0000. Similarly, in 20 patients, enough cells were available from the small volume marrow harvest to assess for growth of clonogenic breast cancer cell colonies. Four patients (20%) had tumor colony growth prior to expansion with three of these patients having detectable breast cancer cell contamination on immunocytochemistry analysis. Following ex vivo expansion, all four patients had no evidence of clonogenic colony growth including the two patients who had persistent detection of breast cancer cell contamination on immunocytochemistry analysis of their expanded bone marrow. Nineteen of the 31 study patients had blood-derived stem cell products, obtained on their first day of apheresis, assessed by immunocytochemistry for malignant cell con-tamination. One patient product (5.3%) was identified to contain one malignant cell in 8 million cells assessed. Samples from 14 patients were available to assess for growth of clonogenic breast cancer cell colonies and none were found to be positive.
Ex vivo expansion potential analysis
Data from 26 of the 31 study patients (no CFU-GM data in three patients, no CD34
+ lineage negative data in two patients), were divided into two groups to determine if the quantity of CD34
+ blood stem cells collected on the first day of apheresis predicted the extent of ex vivo nucleated cell expansion of the small volume bone marrow harvest. Eleven patients with first day apheresis collection containing a CD34
+ cell doses of Ͻ1.0 × 10 6 /kg were compared to 15 patients with first day CD34 + cell doses of у1.0 × 10 6 /kg. There was no significant difference in the nucleated cell expansion between the groups (median twofold vs 2.5-fold; mean 2.2 ± 0.7 vs 2.4 ± 0.5; P = 0.34). Moreover, median CFU-GM expansion was similar in both groups (13.9-fold vs 14.3-fold; mean 23.1 ± 21.4 vs 20.9 ± 17.8; P = 0.78) (Figure 1) . A significant linear correlation was identified, however, between the percentage of CD34 + lineage-negative cells contained in the small volume bone marrow harvest (pre-expansion) and the nucleated cell fold expansion (r = 0.51, P = 0.01) (Figure 2 ). Of note, the percentage of CD34 + lineage-negative cells in the small volume bone marrow harvest did not correlate with the number of blood-derived CD34
+ cells (r = 0.243; P = 0.25) or the blood CD34 + cell dose (CD34 + cells/kg; r = 0.14; P = 0.52) collected on the first day of apheresis.
Single and multivariate analysis
Single-and multivariate analyses were performed to evaluate the data for potential correlation between patient characteristics, infusion variables and engraftment times. The infusion variables that were analyzed included CD34 + cell dose from the apheresis product and CD34
+ lineage-negative cell dose, total nucleated cell dose, and CFU-GM dose all from the ex vivo expanded product. Also analyzed were fold expansion, age of the patient and expanded CFU-F quantity. Based on Spearman rank correlation, the combined CD34
+ cell dose of blood and the CD34 + lineagenegative dose of the ex vivo expanded product gave the best correlation with engraftment of 500 neutrophils/l (r = 0.729, P = 0.001). Total nucleated cell dose from the expanded product gave the best correlation for engraftment of 20 000 platelets/l (r = 0.646, P = 0.001). To a lesser extent, combined blood-derived CD34 + and expanded nucleated marrow cell doses (r = 0.481, P = 0 .006) and blood-derived CD34 + cell dose (r = 0.373; P = 0.04), also correlated with platelet recovery. Independently, bloodderived CD34
+ cell dose correlated better with neutrophil engraftment of 500 cells/l (r = 0.685, P = 0.001) than expanded marrow CD34 + cell dose (r = 0.405, P = 0.03). In contrast, fold expansion correlated with day to neutrophil engraftment (r = 0.35, P = 0.05), but not platelet engraftment (P = 0.30). Patient age inversely correlated with days to engraftment of platelets (r = 0.387, P = 0.035), 6 /kg on the first day of apheresis collection. Nucleated cell and CFU-GM quantities were assessed pre-and post-ex vivo expansion in each patient (ᮀ). Fold expansion was calculated using the formula: total nucleated cells (or CFU-GM) recovered post-expansion/total nucleated cells (or CFU-GM) inoculated pre-expansion.
but not neutrophils (P = 0.31). Expanded CFU-GM dose did not correlate with neutrophil or platelet engraftment. Finally, post-expansion CFU-F quantity did correlate with platelet engraftment (r = 0.551, P = 0.004).
Discussion
The results of our study reveal an effective alternative strategy in place of increasing the number of apheresis procedures to obtain an optimal CD34 + blood-derived stem cell dose for non-rapid mobilizers. Despite receiving what is considered to be an inadequate dose of blood-derived mobilized CD34
+ cells and nucleated bone marrow cells, engraftment was complete and occurred sooner than + lineage-negative cells was determined in each patient (ᮀ) using standard flow cytometry. Fold expansion was calculated using the formula: total nucleated cells recovered postexpansion/total nucleated cell inoculated pre-expansion.
expected in all four blood CD34 + cell dosing cohorts in our study, including patients receiving as few as 0.2 × 10 6
CD34
+ cells/kg. The 31 study patients experienced engraftment of neutrophils (500/l) and platelets (20 000/l) in a median of 10 (range, 9-15) and 13 (range, 6-41) days, respectively. These patients had a median of only 1 day of febrile neutropenia and were discharged from hospital after a median of 11 days. The observed outcomes compare favorably to a historic control group of 99 breast cancer patients (matched for age, prior therapy and disease extent) treated with the same high-dose chemotherapy regimen, who after a median of three apheresis procedures (range, 1-6), received a median mobilized CD34 + blood stem cell dose of 10.8 × 10 6 /kg (range, 3.7-27 × 10 6 /kg). Patients recovered 500 neutrophils/l in a median of 9 days (range, 7-16 days) and 20 000 platelets/l in 11 days (range, 8-32 days). 7 Strikingly, platelet recovery was better than expected as evidenced by comparing the two cohorts of patients receiving р0.5 × 10 6 CD34 + cells/kg in our study to patients from two other studies receiving р0.75 × 10 6 CD34 + cells/kg and р2.5 × 10 6 /kg CD34 + cells/kg. 7, 10 In our study, platelet recovery (20 000 cells/l) in patients from these two cohorts occurred at a median of 19.5 days compared to the 35 and 33 days respectively observed in the other two studies. Moreover, our results appear to be superior when compared to patients who received a non-G-CSF-primed standard volume bone marrow transplant or an ex vivo expanded small volume bone marrow transplant, regardless of G-CSF priming (AastromReplicell system) with reported recoveries of 500 neutrophils/l and 20 000 platelets/l at medians of 14 and 16 and 22 and 24 days, respectively. 16, 24 Despite extensive washing, infusion of the expanded product may result in allergic-type reactions, thus patients need to be observed carefully in a controlled, setting, particularly those with a history of allergy.
Bone Marrow Transplantation
Previous data suggest it is highly unlikely that infusion of either the low blood-derived dose of CD34 + cells or the ex vivo expanded bone marrow alone would have resulted in the engraftment rates and clinical results observed in our patients who received the combination of the two. Unlike prior experiences with the AastromReplicell system, where non-G-CSF-primed fresh bone marrow mononuclear cells were used and CD34
+ lineage-negative cell numbers were preserved during expansion, 16 the actual number of CD34 + lineage-negative bone marrow cells in our study decreased by a median factor of five during expansion. In our study, G-CSF priming may have driven CD34 + lineage-negative bone marrow cells towards myeloid differentiation. Moreover, thawing of cryopreserved bone marrow (as performed in our study) has been shown to result in decreased recovery of CD13
+ myeloid progenitors prior to expansion. 20 Thus, it is also possible that CD34 + lineage-negative bone marrow cells were forced to differentiate during ex vivo expansion to replace these depleted myeloid progenitors, explaining the decrement of CD34 + lineage-negative cells. Hence, it also appears to be highly unlikely that the observed enhanced hematopoietic reconstitutive capacity expanded marrow imparted to low doses of blood-derived CD34 + cells was due solely to increasing the infused CD34
Multivariate analysis revealed the blood CD34 + cell dose and the total expanded nucleated cell dose to be strong predictors of the rate of neutrophil and platelet engraftment, suggesting that the two products had an independent and synergistic effect on engraftment outcomes. A prior study demonstrated an approximate 40-fold increase in stromal progenitors (a component of the total nucleated cell dose) following ex vivo expansion in the AastromReplicel system. 16 Infusion of expanded mesenchymal stem cells, a stromal progenitor, with blood-derived CD34 + cells has been shown to hasten hematopoietic recovery in breast cancer patients treated with high dose chemotherapy. 19 Also, recent reports indicate that mesenchymal cells are capable of supporting long-term growth and retroviral transduction of blood-derived CD34 + cells in culture, presumably due to constitutive secretion of interleukins, macrophage colonystimulating factor, Flt-3 ligand and stem-cell factor. 19, 25, 26 Thus, in addition to the direct effect blood-derived and expanded CD34
+ cells had on engraftment, the infusion of a large quantity of expanded stromal cells may have facilitated growth and maturation of hematopoietic precursors in vivo, particularly platelet precursors, resulting in the unexpectedly prompt rate of hematopoietic recovery observed in our patients, despite infusion of a low total dose of blood and bone marrow-derived CD34 + cells. Facilitation of engraftment by expanded stromal cells is further supported by the observation that the expanded total nucleated bone marrow cell dose, but not expanded CD34
+ lineage-negative bone marrow cell dose, correlated with both engraftment parameters. Also, CFU-F quantity, a component of the stromal cell population, was found to expand a median of 18.8-fold and correlated with platelet engraftment following high-dose chemotherapy. Downregulation of vascular adhesion molecule-1 (VCAM-1) and other defects of in vivo stromal elements have been observed following high-dose chemotherapy. [27] [28] [29] [30] [31] [32] Expan-sion of stromal cells and protection of these cells from highdose chemotherapy in the AastromReplicell system therefore may have contributed to the observed synergy. Our data indicate that the expansion potential of bone marrow is a direct function of the pre-expansion CD34 + lineage-negative content in the small bone marrow harvest (r = 0.51, P = 0.01). Attempts to further improve engraftment results will therefore likely include priming patients with an early acting growth factor (ie stem-cell factor) to increase the starting inocula of CD34 + lineagenegative cells and using early acting platelet growth factors in the expansion medium to drive early CD34 + cell expansion, as well as differentiation more towards platelet precursors. 33, 34 Our analysis also revealed the quantity of CD34 + lineage-negative cells in the small marrow harvest to be independent of the quantity of CD34 + blood stem cells mobilized on the first day of apheresis. Moreover, the expansion potential of the small marrow harvest was found to be independent of the CD34 + blood stem cell quantity collected. Thus, cancer patients who are poor mobilizers may also be able to benefit from the addition of ex vivo expanded bone marrow, assuming their small marrow harvest contains an adequate starting quantity of CD34 + lineage-negative cells.
It is possible that the results observed in our study will not be applicable in the poor mobilizer, because bloodderived stem cells collected in one apheresis procedure from non-rapid mobilizers may possess a greater hematopoietic reconstitutive capacity than those collected from poor mobilizers. Recent data, however, suggest a beneficial effect when adding ex vivo expanded bone marrow, using the AastromReplicell system, to low doses of blood-derived CD34 + cells in heavily pretreated patients with lymphoma, who were poor mobilizers. Here, four patients who were unable to mobilize 2.0 × 10 6 /kg CD34 + cells in one round of multiple aphereses and who had poor marrow cellularity at the time of bone marrow collection despite G-CSF priming, demonstrated expansion results and engraftment rates of neutrophils similar to the breast cancer patients in our study. 35 Platelet recovery also occurred sooner than expected in the two patients who did not receive prior fludarabine chemotherapy. Regardless, a much larger study using this approach in patients who are poor mobilizers is needed to determine the value, if any in this setting.
Of note, approximately 5-15% of patients eligible for autologous blood stem cell transplant will experience difficulty in obtaining an adequate number of CD34 + cells to proceed to transplant, regardless of the mobilization regimen used. 11, 12 Patients from which Ͻ0.6 × 10 6 CD34 + cells/kg are collected in two to three apheresis procedures, or those who have a circulating CD34 + blood content of Ͻ5 cells/l at the time of collection, have been shown to be unlikely to achieve a CD34 + blood stem cell dose Ͼ2.5 × 10 6 /kg in one round of apheresis. 12 Adding a full volume bone marrow harvest to low doses of blood-derived CD34 + cells collected from poor mobilizers has not significantly improved engraftment outcomes. 36 Our results have revealed a promising alternative strategy for further study in this predictable group of poor mobilizers. Particular attention is needed, however, to determine if other factors, including prior exposure to bone marrow toxins, such as fludarabine or cisplatin will adversely influence the observed beneficial effect of adding expanded marrow to low doses of blood-derived CD34 + cells. 37, 38 Increasing the number of aphereses has been associated with an increase in the incidence of contaminating tumor cells. In one large series of patients with metastatic breast cancer, only 5.4% of the first day apheresis products were contaminated with breast cancer cells, while the incidence increased significantly with each additional apheresis, exceeding 30% in patients undergoing three or more apheresis procedures (P = 0.008). 39 Similarly, in our study only 5.3% of the patients sampled on their first day of apheresis had tumor contamination by immunocytochemistry of their blood stem cell product, but none demonstrated growth in a clonogenic assay. Moreover, in our current study, ex vivo expansion resulted in a decrease in the incidence and frequency of bone marrow contamination following expansion and elimination of all breast cancer cells capable of growing in a clonogenic assay.
In conclusion, we have demonstrated a reliable and pathogen-free method of ex vivo expanding nucleated cells obtained from a small volume (Ͻ100 ml) bone marrow harvest. The expanded cells appear to be capable of facilitating engraftment when combined with very low doses of mobilized blood-derived CD34 + cells collected from non-rapid mobilizers. The combination of low doses of blood-derived CD34 + cells, collected in one apheresis procedure, and ex vivo expanded bone marrow should now be further evaluated in prospective randomized trials as a method to enable transplants in poor mobilizers and a means of eliminating malignant cells without adversely affecting engraftment. Further evaluation will determine if this approach provides improved outcomes for a broad range of autologous transplant recipients.
